newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • On March 2, 2026, Praxis Precision Medicines' Compensation Committee granted restricted stock unit awards covering 2,931 shares to fourteen new non-executive employees.
  • The awards were made under the Praxis Precision Medicines, Inc. 2024 Inducement Plan to induce employment in compliance with Nasdaq Listing Rule 5635(c)(4).
  • The plan is used exclusively for equity grants to individuals not previously employed by Praxis or those returning after a bona fide non-employment period.
  • The restricted stock units will vest in four equal annual installments contingent on the employees' continued employment on each vesting date.
  • Praxis is a CNS precision neuroscience biopharmaceutical company developing therapies for neuronal excitation-inhibition imbalance disorders using its Cerebrum™ small molecule platform & Solidus™ antisense oligonucleotide platform.
  • The company currently maintains a diversified CNS portfolio with four late-stage product candidates across movement disorders & epilepsy.